Oppenheimer Upgrades Inspire Medical Systems (NYSE: INSP) Amidst Revenue Dip and Strong Profitability

• Analyst firm Oppenheimer upgraded Inspire Medical Systems (NYSE: INSP) to "Outperform" despite a reported decrease in second-quarter revenue.
• Inspire Medical Systems delivered strong profitability, with quarterly earnings of $0.14 per share, significantly beating analyst expectations of a $0.22 per share loss.
• Inspire Medical Systems raised its full-year financial outlook and announced a new strategic growth plan, aiming to redeploy $30 million for business expansion.

Inspire Medical Systems is a medical technology company that focuses on developing therapies for obstructive sleep apnea. On August 4, 2026, the analyst firm Oppenheimer upgraded Inspire Medical Systems, raising its rating from "Perform" to "Outperform." The stock price was $52.22 at the time the rating was posted.

The upgrade occurs even as Inspire Medical Systems reports a decrease in its second-quarter revenue to $200.6 million, down 7.6% from the prior year. Inspire Medical Systems states this drop is mainly due to ongoing "coding and reimbursement disruptions." These administrative issues have temporarily reduced the number of procedures using its sleep apnea therapy system.

Despite the revenue decline, Inspire Medical Systems delivered strong profitability that beat expectations. As highlighted by Zacks Investment Research, Inspire Medical Systems posted quarterly earnings of $0.14 per share. This result significantly outperformed the Zacks Consensus Estimate, which had predicted a loss of $0.22 per share, representing a positive surprise of 163%.

This performance prompted Inspire Medical Systems to raise its full-year financial outlook for revenue and earnings. Inspire Medical Systems also announced a new strategic growth plan. This plan aims to unlock and redeploy $30 million toward new initiatives designed to expand the business and increase the long-term adoption of its therapy.

Company leadership expresses confidence that the reimbursement challenges will lessen in the second half of 2026. Management notes it is actively working with customers to navigate the changes in billing. This improving operational outlook likely supports the positive view from analysts and the recent stock upgrade.